/
Immunology
Atopic Dermatitis
95
Pipeline Programs↗
189
Active Trials↗
148
Companies Involved↗
Atopic Dermatitis is a moderately active landscape with 95 programs across 148 companies. The most active players are Pfizer, AbbVie, Sanofi. 26 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 111
Phase 234
Phase 326
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
62 of 73 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 73 classified programs, each share of the total. Modality classified for 86% of 95 pipeline programs.
Analysis
Trial Status
866
clinical trials
Completed538 · 62%
Recruiting100 · 12%
Terminated69 · 8%
Active, not recruiting43 · 5%
Not yet recruiting41 · 5%
Unknown status39 · 5%
Other36 · 4%
Clinical Trials
Trial Activity
866 trials
Page 1 of 58
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)